Chondroitin sulfate for treatment of interstitial cystitis
Palylyk-Colwell E
Record ID 32006000851
English
Authors' objectives:
The aim of this report is to assess the available information on the use of chondroitin sulfate for treatment of interstitial cystitis.
Authors' recommendations:
Chondroitin sulfate solution 2.0% is a glycosaminoglycan (GAG) replenishment therapy instilled into the bladder of GAG-deficient patients with interstitial cystitis (IC).
Two non-randomized, uncontrolled pilot studies report improvements in patient-reported symptoms after the use of chondroitin sulfate for one year. Prospective, randomized, head-to-head trials are needed to assess the effectiveness of this technology compared with other IC therapies.
The cost and demand for this technology are low, but there could be a significant impact on clinics that administer treatment, if uptake increases.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
http://www.cadth.ca/
Year Published:
2006
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Costs and Cost Analysis
- Chondroitin Sulfates
- Cystitis, Interstitial
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.